内分泌联合维生素D治疗晚期前列腺癌的效果  

Effects of hormonal therapy regiments and Vitamin D on advanced prostate cancer patients

作　　者：吕建阳[1] 张文[2] 陈林[1] 昌建明[1] 刘晨波[1] 刘殿刚[3] 

机构地区：[1]北京市第六医院泌尿外科,北京100007 [2]北京丰台医院泌尿科,北京100070 [3]首都医科大学宣武医院普外科,北京100053

出　　处：《中国医药导报》2014年第14期53-55,69,共4页China Medical Herald

基　　金：中国博士后科学基金资助项目(编号2012M510094)

摘　　要：目的探讨内分泌联合维生素D治疗晚期前列腺癌的临床效果。方法将43例晚期前列腺癌患者分为对照组(20例)和治疗组(23例),治疗组治疗方案如下:氟他胺,250 mg,每日3次口服,醋酸亮丙瑞林微球蛋白3.75 mg,每月1次,皮下注射;1α-羟基维生素D3,1μg,每日1次口服;3个月为1个周期。对照组接受内分泌治疗而不加用1α-羟基维生素D3。比较两组治疗前后血清总前列腺特异性抗原(T-PSA)降低反应有效率、生活质量评分(QOL)、近期肿瘤原发灶及转移病灶控制。结果治疗组与对照组PSA降低反应总有效率分别为86.95%、50.00%,两组比较差异有统计学意义(P=0.021)。治疗组与对照组肿瘤原发病灶和(或)转移灶有效控制率分别为86.95%、55.00%,两组比较差异有统计学意义(P=0.046)。治疗12个月时治疗组患者QOL评分[(31.86±4.12)分]显著高于对照组[(28.16±5.36)分],差异有高度统计学意义(P<0.01)。结论氟他胺、亮丙瑞林联合维生素D治疗晚期前列腺癌效果明确。Objective To investigate effects of hormonal therapy regiments and vitamin D on advanced prostate cancer patients. Methods 43 advanced prostate cancer patients were randomly divided into control group （20 cases） and treatment group （23 cases）. The therapeutic regimens of treatment group contained Flutamide （250 mg, oral use, 3 times a day）, Leuprorelin Acetate Mierospheres for injection （3.75 mg, subcutaneous injection, once a month）, 1α（OH）D3 （1 μg, oral use, once a day）. One cycle lasted about 3 months. The control group auepted endocrine therap without 1α-OH- VD3 Changes in T-PSA, QOL score and measurable primary tumor or metastasis were measured in two groups at the end points. Results A prostate specific antigen response of greater decrease was 86.95% in treatment group and 50.00% in control group （P = 0.021）; disease control rate was 86.95% in treatment group and 55.00% in control group （P = 0.046）. The scores of QOL were （31.86±4.12） scores at 12 months after treatment in treatment group and （28.16±5.36） scores in control group, the difference was statistically significant （P 〈 0.01）. Conclusion Flutamide, Leuprorelin combined with vitamin D is effective in the treatment of advanced prostate cancer.

关 键 词：晚期前列腺癌 内分泌治疗 维生素D 

分 类 号：R737.25[医药卫生—肿瘤]